Abstract 1490P
Background
Cancer is a debilitating disease that affects both patients and their caregivers. The diagnosis and treatment of cancer could affect the quality life of the patient and their family. Patients undergoing chemotherapy experience physical and emotional symptoms that affect their quality of life. Some of them experienced difficulty sleeping, depression and poor quality of life. Caregivers of cancer patients may have to cope with a variety of physical, social, and economic problems during the caregiving process. Caregivers experienced caregiver strain while providing care for the patient. The caregiver strain influences the quality of care and thus the quality of life of the patient. Hence, this study aims to determine the health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain.
Methods
A cross sectional analytical study was conducted among cancer patients and their caregiver at the Bataan General Hospital and Medical Center. The EORTC core quality of life questionnaire (QLQ-C30) and modified caregiver strain index (MCSI) questionnaires were administered to assess HRQoL and caregiver strain respectively. Descriptive statistics, Pearson correlation and Spearman rank were performed for analysis of quality-of-life parameters and caregiver strain.
Results
A total of 145 cancer patient-caregiver dyads were included in this study. The median global health status among cancer patients was 75 (66.67 to 91.67) suggesting an optimistic view of overall health and quality of life. The median MCSI score was 19 (14 to 24) indicating a moderate to high level of strain. The relationship between health-related quality of life and caregiver strain showed minimal to no meaningful relationship.
Conclusions
Cancer patients generally exhibit satisfactory to high functioning across physical, role, and cognitive functions. The caregiving role, irrespective of the patient's condition, carries intrinsic challenges. Although the relationship between the HRQoL of patients and caregiver strain was very weak, both are important and functions independently.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10